These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 24655213)

  • 1. Eisenmenger syndrome: recent advances in pharmacotherapy.
    Said S; Porres-Aguilar M; Porres-Munoz M; Mukherjee D
    Cardiovasc Hematol Agents Med Chem; 2013 Dec; 11(4):289-96. PubMed ID: 24655213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is the position of pulmonary arterial hypertension-specific drug therapy in patients with Eisenmenger syndrome: A systematic review and meta-analysis.
    Li Q; Kuang HY; Wu YH; Lu TW; Yi QJ
    Medicine (Baltimore); 2019 May; 98(20):e15632. PubMed ID: 31096477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evidence base for specific pulmonary vasodilators in adults with congenital heart disease].
    Shmalts AA; Gorbachevsky SV
    Ter Arkh; 2021 Sep; 93(9):1106-1116. PubMed ID: 36286872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Update pulmonary arterial hypertension : Definitions, diagnosis, therapy].
    Sommer N; Richter MJ; Tello K; Grimminger F; Seeger W; Ghofrani HA; Gall H
    Internist (Berl); 2017 Sep; 58(9):937-957. PubMed ID: 28819824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selexipag in Congenital Heart Disease-Associated Pulmonary Arterial Hypertension and Eisenmenger Syndrome: First Report.
    El-Kersh K; Suliman S; Smith JS
    Am J Ther; 2018; 25(6):e714-e715. PubMed ID: 29521655
    [No Abstract]   [Full Text] [Related]  

  • 6. [Remarkable response of bosentan, an endothelin receptor antagonist, for a patient with Eisenmenger syndrome].
    Emoto N; Matsuo N; Ohnishi T; Miyagawa K; Kato H; Iwasa N; Yoshida A; Kawai H; Hirata K; Kuroda Y
    Nihon Naika Gakkai Zasshi; 2008 Oct; 97(10):2549-51. PubMed ID: 19051748
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension.
    Chau EM; Fan KY; Chow WH
    Int J Cardiol; 2007 Sep; 120(3):301-5. PubMed ID: 17174418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral targeted therapies in the treatment of pulmonary arterial hypertension: a meta-analysis of clinical trials.
    Zheng YG; Ma H; Hu EC; Liu G; Chen G; Xiong CM
    Pulm Pharmacol Ther; 2014 Dec; 29(2):241-9. PubMed ID: 25173912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Eisenmenger syndrome. Specific treatments].
    Acar P
    Presse Med; 2009 Dec; 38 Suppl 1():1S18-22. PubMed ID: 20141997
    [No Abstract]   [Full Text] [Related]  

  • 10. More than a rare cause of pulmonary hypertension in the elderly.
    Plácido R; Sousa I; Antunes D; Guimarães T; Pinto FJ
    Rev Port Cardiol (Engl Ed); 2020 Mar; 39(3):175-176. PubMed ID: 32345560
    [No Abstract]   [Full Text] [Related]  

  • 11. Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension.
    Beghetti M; Galiè N
    J Am Coll Cardiol; 2009 Mar; 53(9):733-40. PubMed ID: 19245962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and advancing treatments for pulmonary arterial hypertension in childhood.
    Zijlstra WM; Ploegstra MJ; Berger RM
    Expert Rev Respir Med; 2014 Oct; 8(5):615-28. PubMed ID: 25047735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Choice of Initial Oral Therapy for Pulmonary Arterial Hypertension: Age and Long-Term Survival.
    Heresi GA; Love TE; Tonelli AR; Highland KB; Dweik RA
    Am J Respir Crit Care Med; 2018 Oct; 198(8):1090-1093. PubMed ID: 29949380
    [No Abstract]   [Full Text] [Related]  

  • 14. Sildenafil in Eisenmenger syndrome: safety first.
    Wort SJ
    Int J Cardiol; 2007 Sep; 120(3):314-6. PubMed ID: 17477991
    [No Abstract]   [Full Text] [Related]  

  • 15. Combination therapy in pulmonary arterial hypertension.
    Pugh ME; Hemnes AR; Robbins IM
    Clin Chest Med; 2013 Dec; 34(4):841-55. PubMed ID: 24267308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Targeted therapy of pulmonary arterial hypertension (PAH)].
    Klose H; Opitz C; Bremer H; Ewert R; Bonderman D; Rosenkranz S; Seeger W; Schmeißer A; Harbaum L; Buerke M; Ghofrani HA; Borst MM; Leuchte HH; Lange TJ; Behr J; Ulrich S; Lang I; Olschewski H; Gall H; Kabitz HJ; Kleber FX; Held M; Hoeper MM; Grünig E
    Dtsch Med Wochenschr; 2014 Dec; 139 Suppl 4():S142-50. PubMed ID: 25489684
    [No Abstract]   [Full Text] [Related]  

  • 17. Eisenmenger syndrome: not always inoperable.
    Huang JB; Liang J; Zhou LY
    Respir Care; 2012 Sep; 57(9):1488-95. PubMed ID: 22348268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pulmonary arterial hypertension: changing approaches to management].
    Sidorenko BA; Preobrazhenskiĭ DV; Batyraliev TA; Belenkov IuN
    Kardiologiia; 2011; 51(1):100-8. PubMed ID: 21626809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Medical treatment of pulmonary hypertension: what's new?].
    Richter MJ; Gall H; Tello K; Sommer N; Seeger W; Grimminger F; Ghofrani HA
    Internist (Berl); 2015 May; 56(5):573-82. PubMed ID: 25924799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of evidence for bosentan therapy for treatment of Eisenmenger syndrome.
    Hartwig BJ; Schultze B
    J Am Assoc Nurse Pract; 2019 Jan; 31(1):72-77. PubMed ID: 30475252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.